Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (Q38188183)

30 August 2017

0 references

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (English)

1 reference

30 August 2017

1 reference

11

1 reference

30 August 2017

17

1 reference

30 August 2017

37

Gunter von Minckwitz

0 references

Wolfgang Eiermann

36

Wolfgang Eiermann

0 references

Pinuccia Valagussa

10

Pinuccia Valagussa

0 references

Sibylle Loibl

13

Sibylle Loibl

0 references

Holger Eidtmann

24

Holger Eidtmann

0 references

Michael Untch

3

Michael Untch

0 references

Josep Baselga

16

Jose Baselga

1 reference

30 August 2017

9

Luca Gianni

0 references

Vladimir Semiglazov

Vladimir Semiglazov

22

0 references

Soonmyung Paik

Soonmyung Paik

25

0 references

Peter A. Fasching

28

Peter A Fasching

1 reference

30 August 2017

Eleftherios P Mamounas

20

Eleftherios P Mamounas

1 reference

30 August 2017

Patricia Cortazar

1

1 reference

30 August 2017

Lijun Zhang

2

1 reference

30 August 2017

Keyur Mehta

4

1 reference

30 August 2017

Joseph P Costantino

5

1 reference

30 August 2017

Norman Wolmark

6

1 reference

30 August 2017

Hervé Bonnefoi

7

1 reference

30 August 2017

David Cameron

8

1 reference

30 August 2017

Tatiana Prowell

12

1 reference

30 August 2017

D Lawrence Wickerham

14

1 reference

30 August 2017

Jan Bogaerts

15

1 reference

30 August 2017

Gideon Blumenthal

18

1 reference

30 August 2017

Jens Blohmer

19

1 reference

30 August 2017

Jonas Bergh

21

1 reference

30 August 2017

Robert Justice

23

1 reference

30 August 2017

Martine Piccart

26

1 reference

30 August 2017

Rajeshwari Sridhara

27

1 reference

30 August 2017

Leen Slaets

29

1 reference

30 August 2017

Shenghui Tang

30

1 reference

30 August 2017

Bernd Gerber

31

1 reference

30 August 2017

Charles E Geyer

32

1 reference

30 August 2017

Richard Pazdur

33

1 reference

30 August 2017

Nina Ditsch

34

1 reference

30 August 2017

Priya Rastogi

35

1 reference

30 August 2017

language of work or name

English

0 references

publication date

14 February 2014

1 reference

30 August 2017

9

1 reference

inferred from page(s)

published in

The Lancet

1 reference

30 August 2017

384

1 reference

30 August 2017

9938

1 reference

30 August 2017

164-172

1 reference

Pathological complete response and accelerated drug approval in early breast cancer

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Preoperative chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

Individual- and trial-level surrogacy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962422-8

7 January 2021

10.1016/S0140-6736(13)62422-8

Identifiers

DOI

1 reference

30 August 2017

1 reference